Phio Pharmaceuticals Corp. is a biotechnology company specializing in the development of groundbreaking therapeutics, particularly in the field of immuno-oncology. Utilizing their proprietary technology platform, they focus on addressing unmet medical needs to potentially enhance cancer treatment outcomes.
PH-762 is the flagship product candidate of Phio Pharmaceuticals, currently in clinical studies. It shows promising potential in enhancing cancer treatment by modulating immune responses to improve therapy outcomes.
PH-762 addresses the critical need for improved cancer therapies by potentially enhancing the effectiveness of immune-oncology treatments.
Need for innovative cancer treatments and enhancement of therapeutic efficacy